Mechanisms of action for metallic elements and their species classif1ed carcinogen R 45 and R 49 by EU in this paper we will deal with mechanism of carcinogenic;Meccanismi di azione per gli elementi metallici e loro specie classificati cancerogeni R45 ed R49 dall'UE - Parte 2

Giornale Italiano di Medicina del Lavoro ed Ergonomia

Volumn 30, Issue 4, 2008, Pages 382-391

  Apostoli, P ^a   Catalani, S ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Carcinogenic action; Carcinogens R45; Mechanisms; Metallic elements and species; R49

Indexed keywords

ARSENIC; BERYLLIUM; CADMIUM; CARCINOGEN; CHROMIUM; COBALT; DNA; HEAVY METAL; METAL; MUTAGENIC AGENT; NICKEL;

CHEMICALLY INDUCED DISORDER; CHEMISTRY; DNA DAMAGE; DNA REPAIR; DRUG EFFECT; EUROPEAN UNION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; NEOPLASM; REVIEW;

ARSENIC; BERYLLIUM; CADMIUM; CARCINOGENS; CHROMIUM; COBALT; DNA; DNA DAMAGE; DNA REPAIR; EUROPEAN UNION; GENE EXPRESSION REGULATION; HUMANS; METALS; METALS, HEAVY; METALS, LIGHT; MUTAGENS; NEOPLASMS; NICKEL;

EID: 62349133722     PISSN: 15927830     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (103)

1. Hengstler JG, Bolt HM et al. Special Issue: Metal Toxicology. Arch Toxicol 2008; 82: 489-571.
2. Beyersmann D, Hartwig A. Carcinogenic metal compounds: recent insight into molecular and cellular mechanisms. Arch Toxicol 2008; 82: 493-512.
3. Arsenic in Handbook on the toxicology of metals, third edition. Nordberg GF, Fowler BA., Nordbger M., Friberg LT. Burlington USA. Elsevier. 2007; 367-406.
4. Tapio S. Grosche B. Arsenic in the aetiology of cancer. Mutat Res 2006; 612: 215-246.
5. Liu YT, Chen Z. A retrospective lung cancer mortality study of people exposed to insoluble arsenic and radon. Lung Cancer 1996; 14: 137-148.
6. Kitchin KT, Wallace K. Arsenite binding to synthetic peptides based on the Zn finger region and the estrogen binding region of the human estrogen receptor-alpha.Toxicol Appl Pharmacol 2005; 206: 66-72.
7. Simeonova PP, Luster MI. Mechanisms of arsenic carcinogenicity: genetic or epigenetic mechenisms?.J Environ Pathol Toxicol Oncol 2000; 19: 281-286.
8. Cohen SM. Ohnishi T. Arnold LL. Le XC. Arsenic induced bladder cancer in a animal model. Toxicol Appi pharmacol 2007; 222: 258-263.
9. Wei M, Wanibuchi H, Morimura K, Iwai S, Yoshida K, Endo G, Nakae D, Fukushima S. Carcinogenicity of dimethylarsinic acid in male F344 rats and genetic alterations in induced urinary bladder tumors. Carcinogenesis; 23: 1387-97.
10. Kligerman AD, Doerr CL, Tennant AH, Harrington-Brock K, Allen JW, Wink Weld E, Poorman- Allen P, Kundu B, Funasaka K, Roop BC, Mass MJ, DeMarini DM Methylated trivalent arsenicals as candidate ultimate genotoxic forms of arsenic: induction of chromosomal mutations but not gene mutations. Environ Mol Mutagen 2003; 42: 192-205.
11. Salnikow K, Zhitkovich A. Genetic and epigenetic in metal carcinogenesis and cocarcinogenesis: Nickel, Arsenic and Chromium. Chem Res Toxicol 2008; 21: 28-44.
12. Dong Z. The Molecular Mechanisms of Arsenic-Induced Cell Transformation and Apoptosis. Environ Health Perspec 2002; 110: 757-759.
13. Huang C, Ma W-Y, Li J, Dong Z. Arsenic induces apoptosis through a c-Jun NH2-terminal kinase-dependent, p53-independent pathway. Cancer Res 1999; 59: 3053-3058.
14. Evans CD, LaDow K, Schumann BL, Savage RE, Caruso J, Vonderheide A, Succop P, Talaska G. Effect of arsenic on benzo[a]pyrene DNA adduct levels in mouse skin and lung. Carcinogenesis 2004; 25: 493-497.
15. Lau AT, Chiu JF. Proteomic and biochemical analyses of in vitro carcinogen-induced lung cell transformation: synergism between arsenic and benzo[a]pyrene. Proteomics 2006; 6: 1619-1630.
16. Maier A, Schumann BL, Chang X, Talaska G, Puga A. Arsenic coexposure potentiates benzo(a)pyrene genotoxicity. Mutat Res 2002; 517: 101-111.
17. Hays AM, Srinivasan D, Witten ML, Carter DE, Lantz RC. Arsenic and cigarette smoke synergistically increase DNA oxidation in the lung. J Environ Pathol Toxicol Oncol 2006; 19: 129-138,
18. Tsai SH, Liang YC, Chen L, Ho FM, Hsieh MS, Lin JK. Arsenite stimulates cyclooxygenase-2 expression through activating IkappaB kinase and nuclear factor kappaB in primary and ECV304 endothelial cells. J Cell Biochem 2002; 84: 750-758.
19. Apostoli P, Battoli D, Alessio L, Buchet JP. Biological monitoring of occupational exposure to inorganic arsenic. Occup Environ Med 1999; 56: 825-32.
20. Lamm SH., Engel A, Kruse MB, Feinleib M, Byrd DM, Lai SH., Wilson R. Arsenic in drinking water and bladder cancer mortality in the United States: an analysis based on 133 US counties and 30 years of observation. J Occup Environ Med 2004; 46: 298- 306.
21. Mahata J, Ghosh P, Sarkar JN, Ray K, Natarajan AT., Giri AK. Effect of sodium arsenite on peripheral lymphocytes in vitro: individual susceptibility among a population exposed to arsenic through in vivo. Toxicol Sci 2004; 76: 271- 279.
22. Soucy N, Ihnat M, Kamat C, Hess L, Post M, Klei L, Clark C, Barchowsky A. Arsenic stimulates angiogenesis and tumorigenesis in vivo. Toxicol Sci 2003; 76: 271- 279.
23. Snow E. Hu Y, Klein C, McCluskey K, Schuliga M, Sykora P. Regulation of redox and DNA repair genes by arsenic: low dose protection against oxidative stress? In: Chappel, W.R., Abernathy, C.O.2003.
24. Zhang TC, Schmitt MT, Mumford JL.Effects of arsenic on telomerase and telomeres in relation to cell proliferation and apoptosis in human keratinocytes and leukemia cells in vitro. Carcinogenesis 2003; 24: 1811 - 1817.
25. Snow ET, Sykoraa P, Durhama TR, Kleinb CB. Arsenic, mode of action at biologically plausible low doses: What are the implications for low dose cancer risk? Toxicology and Applied Pharmacology 2005; 207: S557 - S564.
26. Smith KR, Klei LR, Barchowsky A. Arsenite stimulates plasma membrane NADPH oxidase in vascular endothelial cells. Am J Physiol.: Lung Cell. Mol. Physiol 2001; 280, L442- L449.
27. Bode AM,, Dong ZG. The paradox of arsenic: molecular mechanisms of cell transformation and chemotherapeutic effects. Crit Rev Oncol/Hematol 2002; 42: 5 - 24.
28. Misra UK, Gawdi G, Pizzo SV. Beryllium fluoride-induced cell proliferation: a process requiring P21ras-dependent activated signal transduction and NF-KB-dependent gene regulation J Leukoc Biol. 2002;71:487-494
29. Gordon T, Bowser D. Beryllium: genotoxicity and carcinogenicity. Mutat Res 2003; 10: 533: 99-105.
30. Finch GL, Hoover MD, Hahn FF, Nikula KJ, Belinsky SA, Haley PJ, Griffith WC. Animal Models of Beryllium-induced Lung Disease. Environ Health Perspect 1996; 104S: 973-979.
31. Nishizuka Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C Science 1992; 258: 607-614.
32. Sankaran B, Bhagat S, Senior AE. Inhibition of P-glycoprotein ATPa-se activity by beryllium fluoride. Biochemistry 1997; 36: 6847-6853.
33. Keshava N, Zhou G, Spruill M, Ensell M, Ong TM. Carcinogenic potential and genomic instability of beryllium sulphate in BALB/c-3T3 cells. Mol Cell Biochem 2001; 222: 69-76.
34. Hamada H, Sawyer RT, Kittle LA, Newman LS. Beryllium-stimulation does not activate transcription factors in a mouse hybrid macrophage cell line. Toxicology 2000; 143: 249-261.
35. Sunderman FW Jr. Carcinogenic effects of metals. Fed Proc. 1978 Jan; 37: 40-6.
36. Elinder CG, Kjellström T, Hogstedt C, Andersson K, Spång G. Cancer mortality of cadmium workers. Br J Ind Med 1985; 42: 651-655.
37. Waalkes MP. Cadmium carcinogenesis. Mutat Res 2003; 533: 107- 120.
38. Bertin G, Averbeck D. Cadmium: cellular effects, modifications of biomolecules, modulation of DNA repair and genotoxic consequences (a review) Biochimie 2006; 88; 1549-1559.
39. Waalkes MP. Cadmium carcinogenesis in review. J. Inorg.Biochem 2000; 79: 241-244.
40. Hartwig A, Schwerdtle T. Interactions by carcinogenic metal compounds with DNA repair processes: toxicological implications. Toxicol Lett 2002; 127: 47-54.
41. Waisberg M, Joseph P, Hale B, Beyersmann D. Molecular and cellular mechanism od cadmium carcinogenesis. Toxicology 2003; 192:95-117.
42. Liu J, Kadiiska MB, Cotton JC, Qu W, Waalkes MP, Mason RP, Liu Y, Klaassen CD. Acute cadmium exposure induces stress-related gene expression in wild-type and metallothionein-I/II-null mice. Free Radic Biol Med 2002; 32: 525-35.
43. Zikic RV, Stajn AS, Ognjanovic BI, Saicic ZS. Kostic MM, Pavlovic SZ, Petrovic VM. The effect of cadmium and selenium on the antioxidant enzyme activities in rat heart. J Environ Pathol Toxicol Oncol 1998; 17,: 259-264
44. Misra RR, Crance KA, Bare RM, Waalkes MP. Lack of correlation between the inducibility of metallothionein oxidative stress. Cell Biol Toxicol 1997; 18:29-42.
45. 6+ stresses] Ying Yong Sheng Tai Xue Bao 2002 Apr; 13: 510-2.
46. Grasseschi RM, Ramaswamy RB, Levine DJ, Klaassen CD, Wesselius LJ. Cadmium accumulation and detoxification by alveolar macrophages of cigarette smokers. Chest 2003; 124: 1924-1928.
47. Takiguchi M, Achanzar WE, Qu W, Li G, Waalkes MP. Effects of cadmium on DNA-(cytosine-5) methyltransferase activity and DNA methylation status during cadmium-induced cellular transformation. Exp Cell Res 2003; 286: 355-365.
48. Achanzar WE, Achanzar KB, Lewis JG, Webber MM, Waalkes MP. Cadmium induces c-myc, p53, and cjun expression in normal human prostate epithelial cells as a prelude to apoptosis. Toxicol Appl Pharmacol 2000; 164: 291-300.
49. Joseph P, Muchnok TK, Klishis ML, Roberts JR, Antonini JM, Whong WZ, Ong T. Cadmium-induced cell transformation and tumorigenesis are associated withtranscriptional activation of c-fos, c-jun, and c-myc proto-oncogenes: role of cellular calcium and reactive oxygen species. Toxicol Sci 2001; 61: 295-303.
50. Thevenod F, Friedmann JM, Katsen AD, Hauser IA. Up-regulation of multidrug resistance P-glycoprotein via nuclear factor-kappa- activation protects kidney proximal tubule cells from cadmium- and reactive oxygen species-induced apoptosis. J Biol Chem 2000; 275: 1887-1896.
51. Qu W, Fuquay R, Sakurai T. Waalkes MP. Acquisition of apoptotic resistance in Cadmium-induced malignant transformation: specific perturbation of JNK signal transduction pathway and associated Metallothionein over expression. Mol Carcinog 2006; 45: 561-571.
52. Prozialeck WC, Lamar PC, Lynch SM. Cadmium alters the localization of N-cadherin, E-cadherin, and-catenin in the proximal tubule epithelium. Toxicol Appl Pharmacol 2003; 189: 180-195.
53. Shih CM, Wu JS, Ko WC, Wang LF, Wei YH, Liang HF, Chen YC, Chen TC. Mitochondria-mediated caspase-independent apoptosis induced by cadmium in normal human lung cells. J Cell Biochem 2003; 89: 335-347.
54. Nordberg GF, Biomarkers of exposure, effects and susceptibility in humans and their application in studies of interactions among metals in China. Toxicol Letter, in press
55. Nordberg GF, Jin T, Zhang A, Buchet JP, Bernard A. Biomarkers of cadmium and arsenic interactions. Toxicol Appl Pharmacol 2005; 206: 191-197.
56. Kraus T, Schramel P, Schaller KH, Zobelein P, Weber A, Angerer J. Exposure assessment in the hard metal manufacturing industry with special regard to tungsten and its compounds. Occup Environ Med 2001; 58: 631-4.
57. IARC, Clorinated Drinking-water; Chlorination By-products; Some Other Halogenated Compounds; Cobalt and Cobalt Compounds. 1991, Vol. 51.
58. Merritt K, Brown SA, Sharkey NA. Blood distribution of nickel, cobalt, and chromium following intramuscular injection into hamsters. J Biomed Mater Res 1984; 18: 991-1004.
59. Zou W, Zeng J, Zhuo M, Xu W, Sun L, Wang J, Liu XJ. Involvement of caspase-3 and p38 mitogen-activated protein kinase in cobaltchloride-induced apoptosis in PC12 cells Neurosci Res 2002; 15; 67: 837-43.
60. Semenza GL, Roth PH, Fang HM, Wang GL. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. Biol Chem 1994; 23; 269: 23757-63.
61. Karovic O, Tonazzini I, Reboia N, Edström E, Lövdahl C, Fredholm BB, Daré E. Toxic effects of cobalt in primary cultures of mouse astrocytes. Similarities with hypoxia and role of HIF-lalpha. Biochem Pharmacol 2007; 73: 694-708.
62. Battaglia V, Compagnone A, Bandino A, Bragadin M, Rossi CA, Zanetti F, Colombano S, Grillo MA, Toninello A. Cobalt induces oxidative stress in isolated liver mitochondria responsible for permeability transition and intrinsic apoptosis in hepatocyte primary cultures. Int J Biochem Cell Biol 2008; 31.
63. Suzuki Y, Shimizu H, Nagae Y, Fukumoto M, Okonogi H, Kadokura M. Micronucleus test and erythropoiesis: effect of cobalt on the induction of micronuclei by mutagens.Environ Mol Mutagen 1993; 22: 101-6.
64. Lloyd DR, Phillips DH, Carmichael PL. Generation of putative intrastrand cross-links and strand breaks in DNA bytransition metal ion-mediated oxygen radical attack. Chem Res Toxicol 1997; 10: 393-400.
65. Méplan C, Richard MJ, Hainaut P. Metalloregulation of the tumor suppressor protein p53: zinc mediates the renaturation of p53 after exposure to metal chelators in vitro and in intact cells. Oncogene 2000; 19: 5227-36.
66. Lison D, De Boeck M, Verougstraete V, Kirsch-Volders M. Update on the genotoxicity and carcinogenicity of cobalt compounds. Occup Environ Med 2001; 58: 619-625
67. Lison D, Lauwerys R. Study of the mechanism responsible for the elective toxicity of tungsten carbide-cobalt powder toward macrophages. Toxicol Lett 1992; 60: 203-10.
68. Lison D, Carbonnelle P, Mollo L, Lauwerys R, Fubini B. Physicochemical mechanism of the interaction between cobalt metal and carbide particles to generate toxic activated oxygen species. Chem Res Toxicol 1995; 8: 600-6.
69. De Boeck M, Lison D, Kirsch Volders M. Evaluation of the in vitro direct and indirect genotoxic effects of cobalt compounds using the alkaline comet assay. Influence of interdonor and interexperimental variability. Carcinogenesis 1998; 19: 2021-9.
70. International agency for research on cancer. Chromium, Nickel and Welding. Lyon, IARC 1990, Vol. 49.
71. Dayan A.D, Paine AJ. Mechanisms of chromium toxicity, carcinogenicity and allergenicity: review of literature from 1985 to 2000. Hum Exp Toxicol 2001; 20: 439-451.
72. De Flora S, Morelli A, Basso C, Romano M, Serra D, De Flora A. Prominent role of DT-diaphorase as a cellular mechanism reducing chromium(VI) and reverting its mutagenicity. Cancer Res 1985; 45: 3188-3196.
73. De Flora S, Bagnasco M, Serra D, Zanacchi P. Genotoxicity of chromium compounds. A review. Mutat Res 1990; 238: 99-172.
74. De Flora S. Threshold mechanisms and site specificity in chromium(VI) carcinogenesis. Carcinogenesis 1990; 21: 533-541.
75. Langård S. Chromium carcinogenicity; a review of experimental animal data. Sci Total Environ 1988; 71: 341-50.
76. De Flora S. Threshold mechanisms and site specificity in chromium(VI) carcinogenesis.Carcinogenesis 2000; 21: 533-541.
77. Agency for toxic substances and disease registry (ATSDR). Toxicological Profile for Chromium. 2008.
78. Cohen SM, Meek ME, Klaunig JE, Patton DE, Fenner-Crisp PA. The human relevance of information on carcinogenic modes of action: overview. Crit Rev Toxicol 2003; 33: 581-9.
79. Gibb HJ, Lees PS, Pinsky PF, Rooneym BC. Lung cancer among workers in chromium chemical production. Am J Ind Med 2000; 38: 115-126.
80. Park RM, Bena JF, Stayner LT, Smith RJ, Gibb HJ, Lees PS. Hexavalent chromium and lung cancer in the chromate industry: a quantitative risk assessment. Risk Anal 2004; 24: 1099-1108.
81. De Flora S, Iltcheva M, Balansky RM. Oral chromium(VI) does not affect the frequency of micronuclei in hematopoietic cells of adult mice and of transplacentally exposed fetuses. Mutat Res 2006; 610: 38-47.
82. De Flora S, D'Agostini F, Balansky R, Micale R, Baluce B, Izzotti A. Lack of genotoxic effects in hematopoietic and gastrointestinal cells of mice receiving chromium(VI) with the drinking water. Mutat Res 2008; 659: 60-7.
83. Beyersmann D. Effect of carcinogenic metals on gene expression. Toxicol Lett 2002; 28: 63-68.
84. Sugden KD, Campo CK, Martin BD. Direct oxidation of guanine and 7,8-dihydro-8-oxoguanine in DNA by a high-valent chromium complex: a possible mechanism for chromate genotoxicity. Chem Res. Toxicol 2001; 14: 1315-1322.
85. Arakawa H, Ahmad R, Naoui M, Tajmir-Riahi HA. A comparative study of calf thymus DNA binding to Cr(III) and Cr(VI) ions. Evidence for the guanine N-7-chromium-phosphate chelate formation. J Biol Chem 2000; 275: 10150-10153.
86. Bose RN, Moghaddas S, Mazzer PA, Dudones LP, Joudah L, Stroup D. Oxidative damage of DNA by Cr(VI) complexes: relative importance of base versus sugar oxidation. Nucl Acids Res 1999; 27; 2219-2229.
87. Valko M, Morris H, Cronin MTD. Metals, toxicity and oxidative stress. Curr med chem 2005; 12: 1161-1208.
88. Wang S, Shi X. Mechanisms of Cr(VI)-induced p53 activation: the role of phosphorylation, mdm2 and ERK. Carcinogenesis 2001; 22: 757-762.
89. Ha L, Ceryak S, Patierno SR. Chromium (VI) activates ataxia telangiectasia mutated (ATM) protein. Requirement of ATM for both apoptosis and recovery from terminal growth arrest. J Biol Chem 2003; 16: 17885-17894
90. Kiilunen M, Utela J, Rantanen T, Norppa H, Tossavainen A, Koponen M, Paakkulainen H, Aitio A. Exposure to soluble nickel in electrolytic nickel refining. Ann Occup Hyg 1987; 4: 167-88.
91. Valsania MC, Pavan I, Pira E. Specie cancerogene del nichel: esperienze analitiche su matrici ambientali. Atti del convegno nazionale, i valori di riferimento nella stima e gestione del rischio cancerogeno, 13 dicembre 2004, pp 56-60.
92. Zatka VJ, Warner JS, Maskery D. Chemical speciation of nickel in airborne dusts: analytical method and results of an interlaboratory test program. Env Sci tecnol 1992; 26: 138-144.
93. Oiler AR. Respiratory Carcinogenicity Assessment of Soluble Nickel Compounds. Environ Health Perspect 2003; 110: 841-844.
94. Oiler AR, Costa M, Oberdörster G. Carcinogenicity assessment of selected nickel compounds. Toxicol Appl Pharmacol 1997; 143: 152-166.
95. Lee YW, Klein CB, Kargacin B, Salnikow K, Kitahara J, Dowjat K, Zhitkovich A.Christie NT, Costa M. Carcinogenic nickel silences gene expression by chromatin condensation and DNA methylation: a new model for epigenetic carcinogens. Mol Cell Biol 1995; 15: 2547-57.
96. Salnikow K, Donald SP, Bruick RK, Zhitkovich A, Phang JM, Kasprzak KS. Depletion of intracellular ascorbate by the carcinogenic metals nickel and cobalt results in the induction of hypoxic stress. J Biol Chem 2004; 279: 40337-40344.
97. Semenza GL. Wang GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721-732
98. Salnikow K. Kasprzak KS. Nickel Ascorbate Depletion: A Critical Step in Nickel Carcinogenesis? Environ Health Perspect 2005; 113: 577-584.
99. Savolainen H. Biochemical and clinical aspects of nickel toxicity. Rev Environ Health 1996; 11: 167-73.
100. Lu H, Shi X, Costa M, Huang C. Carcinogenic effect of nickel compounds. Mol Cell Biochem 2005; 279: 45-67.
101. Kasprzak KS, Sunderman FW Jr, Salnikow K. Nickel carcinogenesis. Mutat Res 2003; 533: 67-97.
102. Hu W, Feng Z., Tang MS.Nickel (II) enhances benzo[a]pyrene diol epoxide-induced mutagenesis through inhibition of nucleotide excision repair in human cells: a possible mechanism, for nickel (II)-induced carcinogenesis. Carcinogenesis 2004; 25: 455-462.
103. Oiler AR, Costa M, Oberdörster G. Carcinogenicity assessment of selected nickel compounds. Toxicol Appl Pharmacol 1997; 143: 152-66.